Adagene (ADAG) logo

Adagene (ADAG) stock

Cancer immunotherapies , market cap $135M

$1.76
-12.44%

Why is ADAG down?

Down 12% on Nov 20, a down day for the market: the S&P 500 fell 4%, 84% of stocks fell, and biotech stocks a median 3%.

  • Adagene fell 12% that day while biotech stocks fell a median 3%: it trailed its group by 9 points.

No filing or headline in our sources explains it.

Sources: Price history, Nov 20, 2026

−2Long-term trend below a falling 200-day average, down over two years

Tell me next time ADAG moves

Free account, no card. An optional alert when ADAG moves or its score changes.Pro, $1 for a first month. An optional alert when ADAG moves or its score changes.Pro, 7 days free with a card. An optional alert when ADAG moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
Quality Score
-6
Poor
In its industry
#196of 273
Checks firing
1of 14
Trending down
From 52-week high
-63.7%
under its best in a year

Follow ADAG's trial news. Pro members can get an alert when Adagene files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ADAG files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“…with and without liver metastases, sponsored and conducted by Incyte, is expected to begin later this year…”Trial start · SEC filing · Aug 12

Key facts on ADAG

Key facts on ADAG
Holding it back42.5% more shares than a year ago from Massive's market data
Latest filing6-K, Nov 19 Issued a release: "Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2×CD3 Double-Masked Bispecific T-Cell Engager"

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

ADAG catalysts

Coming up

What's next for ADAG, and how long its cash lasts

Next step the company has named

2026“A Phase 1 combination study in 3L MSS CRC patients with and without liver metastases, sponsored and conducted by Incyte, is expected to begin later this year.”Trial start · SEC filing · Aug 12

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsPhase 1/2 · Recruiting · 186 people · main data estimated Jun 30, 2027 · NCT05405595

1 more trial, 1 more milestone and 30 filings, for Pro members.

Cash runway Dec 31, 2025 balance sheet

$74.5M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into late 2028” (8-K, Aug 12). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (F-3, filed May 9, 2025)
  • At-the-market share sales program (424B5, filed May 30, 2025)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CFO Man Kin Tam bought 2,000 shares on Sep 23. 3 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Peter Luo’s 11 filings and quotes.

Get an alert when ADAG files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How ADAG ranks in Biotech

ADAG is #196 of 273 by Quality Score.

How ADAG ranks in Biotech
RankStockQuality Score
196Adagene (ADAG) logoADAGAdagene-6

More in Biotech

ADAG sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $7.7M in 2025. It lost money in each of the eight years.

ADAG has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on ADAG, and all 14 on every stock.Get in free →See the top 3 →Start Pro

ADAG RSI on Nov 20: 39.5, below its 50-day and 200-day averages

Not scored

RSI 39.5, MACD below signal, below both averages. Not scored.

The deep dive on ADAG

6 more findings on ADAG, each with its source, for Pro members.

ADAG share count over time

Shares: 4.8% more than a year ago (to Dec 31).

Shares of ADAG outstanding, as filed
Shares
outstanding
As
of
59.2MDec 31, 2025
58.9MDec 31, 2024
55.1MDec 31, 2023
54.1MDec 31, 2022
Offerings, shelves, and splits of ADAG, from its filings
From its
filings
Filed
Priced a sale of sharesApr 2, 2026
Registered shares for a later sale (F-3)Oct 31, 2025
Set up an at-the-market program for its sharesMay 30, 2025
Registered shares for a later sale (F-3)May 9, 2025

ADAG insider trades

3 insiders bought $162K across 5 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyMan Kin Tam$6KChief Financial Officerat $3.00 on Sep 23, filed Sep 25

All 5 insider filings on ADAG from the last six months, for Pro members.

All ADAG insider trades

ADAG's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

About Adagene

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

128 employeesadagene.com

What Adagene says it competes with

“The biotechnology and pharmaceutical industries are highly competitive and characterized by continuing technological advancement, significant competition and an emphasis on intellectual property.”

From its annual report, SEC filing · Apr 1, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ADAG and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn ADAG's score around: 7 things
  • 8 more filings explained, a plain line each
  • 3 more things pulling ADAG's score down
BreakawaySep 25Man Kin Tam bought ADAG$6K at $3.00, filed Sep 25

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: ADAG's Quality Score is -6 (Poor), #196 of 273 in Biotech. Insiders bought $162K in the last 6 months (Form 4).

What does ADAG's Quality Score say?

ADAG scores -6 today, which Breakaway calls Poor. It is #196 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 12% on Nov 20, a down day for the market: the S&P 500 fell 4%, 84% of stocks fell, and biotech stocks a median 3%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ADAG's Quality Score?

ADAG scores -6 today, which Breakaway calls Poor (below zero). That is #196 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ADAG's -6.

Are insiders buying ADAG?

3 insiders bought $162K across 5 filings in the last 6 months. No open-⁠market sales on record. The newest is Man Kin Tam, Chief Financial Officer, who bought $6K on Sep 23. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Adagene: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.